Capping Lawyers’ Tobacco Fees

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

WASHINGTON--One of Shakespeare’s characters wanted to "kill all the lawyers." Rep. Scott McInnis (R-Colo) just wants to cap their legal fees, at least in any national tobacco agreement. In introducing a bill to limit any legal fees from a settlement to $150 an hour plus expenses, Rep. McInnis noted that some states have entered into contracts with private attorneys that called for payments of up to 25% of funds collected from tobacco cases.

WASHINGTON--One of Shakespeare’s characters wanted to "kill all the lawyers." Rep. Scott McInnis (R-Colo) just wants to cap their legal fees, at least in any national tobacco agreement. In introducing a bill to limit any legal fees from a settlement to $150 an hour plus expenses, Rep. McInnis noted that some states have entered into contracts with private attorneys that called for payments of up to 25% of funds collected from tobacco cases.

"I hope this legislation will serve to initiate the debate regarding how the money from a tobacco settlement deal is to be allocated," he said. "I believe that the funds would best be used to prevent underage smoking, not to line the pockets of a few trial attorneys."

For example, lawyers in the recent multibillion dollar Texas settlement stand to collect $2.2 billion under their contract with the state.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content